Mostrar Notícias:

BMYPrincipaisÚltima HoraBovespa - Brasil

 Ver notícias de outros activos

Pesquisa de notícias relativas à acção Bristol-Myers Squ (ordenadas pela data):

Upgrades: BMY, CPQQ, JOYG Forbes This morning, Jefferies upgraded shares of Bristol-Myers (BMY) from hold to buy as the firm expects big returns from the company's new drugs. ... Watch for Shares of Bristol-Myers Squibb (BMY) to Approach Resistance at $26.30Comtex Smartrend Pipeline Review: Bristol-Myers Squibb's 5 Keys to SuccessMotley Fool More Upside for BMYTrading Markets (press release) Emailwire (press release) (blog) -BloggingStocks (blog) all 27 news articles »

Hapoalim Securities Has Positive Thoughts On Bristol Myers (BMY) Benzinga Hapoalim Securities is reiterating its Hold rating and $23 price target on shares of Bristol Myers Squibb Co. (NYSE: BMY), after its dapagliflozin drug ... Bristol-Myers Squibb and Pfizer Inc Evaluate Unmet Need in Patients with ...MarketWatch (press release) all 41 news articles »

UBS Maintains a 'Neutral' on Bristol-Myers (BMY); Very Strong Apixaban Data StreetInsider.com (subscription) Shares are hitting a morning high, up $0.34 (+1.30%) to $26.42. To see all the upgrades/downgrades on shares of BMY, visit our Analyst Ratings page.

The Star-Ledger - NJ.com

Bayer and Bristol's rival clot drugs both impress Reuters DE) and Bristol-Myers Squibb (BMY.N) both impressed in clinical trials, keeping them firmly in the race to displace the old, problematic heart drug warfarin ... Blood Thinner From Pfizer, Bristol Halves Stroke Rate In StudyNASDAQ Catalyst for Pfizer and Bristol Expected in 2011Minyanville.com The Fight for Market Share in Blood Thinners Is OnSeeking Alpha (blog) all 58 news articles »

Traders Ride the Bull in Bristol-Myers Squibb as Call Volume Surges (BMY) Comtex Smartrend Shares of Bristol-Myers Squibb (NYSE:BMY) traded 1.7% lower yesterday, closing at $26.02. The stock has been drifting lower over the past nine ... and more »

Fatter Wallet. Up 22%. Still Risky. Motley Fool By comparison, Allergan (NYSE: AGN) got $40 million from Bristol-Myers Squibb (NYSE: BMY) for its pain drug -- which hasn't even entered phase 2 development ... and more »

Watch for Shares of Bristol-Myers Squibb (BMY) to Approach Resistance at $26.53 Comtex Smartrend SmarTrend has detected shares of Bristol-Myers Squibb (NYSE:BMY) have bullishly opened above the pivot of $26.05 today and have reached the ... Pharma Stocks Wrap Up - Lower: BMY, GSK, KGTradersHuddle.com Buyers Accumulating Shares of Bristol-Myers Squibb on 1x Above-Average Volume ...Benzinga all 8 news articles »

SunTrust Banks: Upgrades, Downgrades TheStreet.com Bristol-Myers (BMY) upgraded at Jefferies to Buy from Hold on increased expectations for apixaban and ipilimumab, and a low risk of losing US exclusivity ... and more »

Notable Analyst Rating Changes 08/31: GPS, ANF, BMY, UBS Upgraded; HPQ, DGIT ... StreetInsider.com (subscription) Jefferies upgrades Bristol-Myers Squibb Company (NYSE: BMY) from Hold to Buy with a $30 price target. Nomura Securities upgrades UBS AG (NYSE: UBS) from ... and more »

Stock Upgrades: (IHG, ANF, GPS, BMY) StockMister Bristol Myers Squibb Co. (NYSE:BMY) rose 0.62% to $26.01 after Jefferies upgrades the stock from Hold to Buy with a $30 price target. ...

ZymoGenetics Announces Completion of Enrollment in Phase 2b Clinical Trial ... MarketWatch (press release) ZymoGenetics is investigating PEG-Interferon lambda in collaboration with Bristol-Myers Squibb Company (NYSE:BMY) for the treatment of HCV infection. ... and more »

TopNews New Zealand

Astra's Brilinta wins early backing in guidelines Reuters PA) and Bristol-Myers Squibb's (BMY.N). It is expected to win a green light to go on sale in the United States as early as next month, after being endorsed ... New Anti-Clotting Drugs May Have Edge Over Top-Selling PlavixDailyFinance AstraZeneca's Brilinta Needs No Genetic Testing - StudyWall Street Journal Gene testing war looms for AstraZeneca heart drugReuters all 52 news articles »

The Market Oracle

Thursday Options Recap Seeking Alpha (blog) Bristol Myers (BMY) is off 22 cents to $25.86 and options volume is 2X the recent average daily, with about 16K calls and 6880 puts traded so far. ... Reverse Head & Shoulders Pattern 08-26-2010Benzinga all 29 news articles »

Focus on exchange-traded funds that offer attractive yields Houston Chronicle ... and pharmaceutical companies Glaxo (GSK, 5.2 percent yield) and Bristol Myers (BMY, 5.1 percent yield). The high-yield bond fund is a closed-end fund, ... and more »

PRESS DIGEST - New York Times business news - Sept 1 Reuters Bristol-Myers Squibb Co's (BMY.N) experimental anticoagulant drug apixaban worked better than aspirin in preventing stroke and systemic blood clots for ... and more »

Bears Hedge Bets with Calls on Origin Agritech Limited Schaeffers Research Bristol Myers (BMY) is off 22 cents to $25.86 and options volume is 2X the recent average daily, with about 16K calls and 6880 puts traded so far. ... and more »

Post Earnings Update: Bristol-Myers Squibb Has Trended 5.74% Higher In Past 15 ... Comtex Smartrend When Bristol-Myers Squibb (NYSE:BMY) reported earnings 15 days ago on July 22, 2010, analysts, on average, expected the company to report ... Most Active Drug Stocks (MRX, SQNM, PFE, BMY)StockMister all 4 news articles »

US HOT STOCKS: Saks, Lions Gate, Alimera, Dean Foods Wall Street Journal An experimental blood-thinning drug from Bristol-Myers Squibb Co. (BMY, $26.09, +$0.24, +0.93%) and Pfizer Inc. (PFE, $16.05, +$0.19, +1.20%) cut the rate ... and more »

Ipilimumab Receives FDA Priority Review Designation for Adult Patients with ... MarketWatch (press release) PRINCETON, NJ, Aug 18, 2010 (BUSINESS WIRE) -- Bristol-Myers Squibb Company (NYSE:BMY) today announced that the US Food and Drug Administration (FDA) has ... Bristol-Myers Squibb files melanoma drug ipilimumab BLA; gets FDA priority reviewThe Pharma Letter (subscription) Good News For BMY PipelineDaily Markets all 57 news articles »

Bristol-Myers Squibb and ADAP Crisis Task Force Announce Enhanced, Multi-year ... MarketWatch (press release) PRINCETON, NJ & WASHINGTON, Aug 11, 2010 (BUSINESS WIRE) -- Bristol-Myers Squibb Company (NYSE:BMY) and the ADAP Crisis Task Force (ACTF) today announced an ... and more »

Jazz Pharmaceuticals has the Best Relative Performance in the Healthcare ... Comtex Smartrend Biovail (NYSE:BVF) follows with a gain of 1.59% and Bristol-Myers Squibb (NYSE:BMY) rounds out the top five with a gain of 1.24%. ... and more »

U.S. FDA gets tougher with certain drug trials Reuters N) antibiotic Noxafil, Bristol-Myers Squibb Co's (BMY.N) HIV drug Reyataz and Novartis' (NOVN.VX) anemia drug Exjade. Fifteen other drugs were also approved ... and more »

Indicated Dividend Yield Ranking for the S&P 500 by Industry Bloomberg ... Biotechnology & Lif 3.58 54.0 LLY Eli Lilly & Co 5.77 0.49 40.1 BMY Bristol-Myers Squibb Co 4.95 0.32 59.3 PFE Pfizer Inc 4.54 0.18 58.5 MRK Merck & Co ... and more »

Call Player Counts on WellPoint, Inc. to Tackle Resistance Schaeffers Research Bristol Myers (BMY) is off 22 cents to $25.86 and options volume is 2X the recent average daily, with about 16K calls and 6880 puts traded so far. ... and more »

Lupus study suggests blood-thinner drugs may help Reuters PA) and Bristol-Myers Squibb's (BMY.N) Plavix could prevent flare-ups of the disease. "These observations open a possible therapeutic avenue for human ... and more »

Eisai heart drug looks safe in mid-stage trials Reuters PA) and Bristol-Myers Squibb's (BMY.N) $9.5 billion-a-year blockbuster Plavix. Its new drug works in a similar way to Merck & Co's (MRK. ... and more »

A Brief Reprieve TheStreet.com (subscription) (blog) We would buy Bristol-Myers Squibb (BMY - commentary - Trade Now) through $32. Instead, it is mixed. Which allows us to do a drive-by buy of Freeport-McMoRan ... and more »

Watch for Bristol-Myers Squibb to Pullback after Gaining 0.89% Yesterday (BMY) Comtex Smartrend Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $25.97 to a high of $26.34. ... and more »

King Pharmaceuticals - Best Performing Pharmaceutical TradersHuddle.com Also among the worst performers was Bristol-Myers Squibb (NYSE:BMY), which closed the trading session at $26.41 representing 1.27% from the previous trading ... and more »

Shocker: Sanofi's Interested in Genzyme Motley Fool Unless someone comes over the top -- like Eli Lilly (NYSE: LLY) did, when it outbid Bristol-Myers Squibb (NYSE: BMY) for ImClone Systems -- it can be hard ... and more »